Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 10/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 10/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20857082 | 0.89 | RXRA (0.48) | RXRAGRIN1GRIN2BCA1CA2 | |
| SCHEMBL20047046 | 0.87 | RXRA (0.41) | RXRAGRIN1GRIN2BCA1CA2 | |
| SCHEMBL20047001 | 0.87 | RXRA (0.41) | RXRAGRIN1GRIN2BCA1CA2 | |
| SCHEMBL20047076 | 0.87 | CA1 (0.43) | RXRAGRIN1GRIN2BCA1CA2 | |
| SCHEMBL17482381 | 0.87 | CA2 (0.43) | RXRAGRIN1GRIN2BCA1CA2 | |
| SCHEMBL19276551 | 0.86 | RXRA (0.42) | RXRAGRIN1GRIN2BCA1CA2 | |
| SCHEMBL18818621 | 0.86 | RXRA (0.41) | RXRAGRIN1GRIN2BCA1CA2 | |
| SCHEMBL22252456 | 0.85 | CA1 (0.49) | RXRAGRIN1GRIN2BCA1CA2 | |
| SCHEMBL21669973 | 0.84 | RXRA (0.40) | RXRAGRIN1GRIN2BCA1CA2 | |
| SCHEMBL18818594 | 0.84 | RXRA (0.40) | RXRAGRIN1GRIN2BCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210353781-A1 | SURFACE-MODIFIED CELLS, METHODS OF MAKING AND USING | UNITED STATES GOVERNMENT | 2021-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353781-A1 | SURFACE-MODIFIED CELLS, METHODS OF MAKING AND USING | CD4, EPCAM, CD2 | RXRA 1948/4885GRIN1 1191/4885GRIN2B 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.